Zhejiang Shengda Pharm (SHG:603079) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Shengda Pharm (603079)
Zhejiang Shengda Pharm (SHG:603079) has a market capitalization of $347.15 Million (CN¥2.37 Billion) as of September 17, 2026. Listed on the SHG stock exchange, this China-based company holds position #14196 globally and #4221 in its home market, demonstrating a -4.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Shengda Pharm's stock price CN¥12.55 by its total outstanding shares 189029624 (189.03 Million). Also see 603079 current and non-current assets for a full breakdown of the balance sheet.
Zhejiang Shengda Pharm Market Cap History: 2017 to 2026
Zhejiang Shengda Pharm's market capitalization history from 2017 to 2026. Data shows growth from $701.98 Million to $347.15 Million (1.96% CAGR). Also see cash flow conversion of Zhejiang Shengda Pharm for how efficiently the company converts equity into cash flow.
Zhejiang Shengda Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Shengda Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Zhejiang Shengda Pharm for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.58x
Zhejiang Shengda Pharm's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.89x
Zhejiang Shengda Pharm's market cap is 7.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $701.98 Million | $508.56 Million | $72.61 Million | 1.38x | 9.67x |
| 2018 | $305.06 Million | $492.71 Million | $44.54 Million | 0.62x | 6.85x |
| 2019 | $756.04 Million | $519.15 Million | $47.03 Million | 1.46x | 16.08x |
| 2020 | $576.52 Million | $867.31 Million | $197.44 Million | 0.66x | 2.92x |
| 2021 | $470.87 Million | $789.73 Million | $75.76 Million | 0.60x | 6.22x |
| 2022 | $345.49 Million | $738.02 Million | $31.48 Million | 0.47x | 10.97x |
| 2023 | $403.02 Million | $727.41 Million | -$54.06 Million | 0.55x | N/A |
| 2024 | $372.59 Million | $827.40 Million | $29.42 Million | 0.45x | 12.66x |
| 2025 | $490.15 Million | $844.54 Million | $62.16 Million | 0.58x | 7.89x |
Competitor Companies of 603079 by Market Capitalization
Companies near Zhejiang Shengda Pharm in the global market cap rankings as of September 17, 2026. Review 603079 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Shengda Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Zhejiang Shengda Pharm Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Shengda Pharm's market cap moved from $701.98 Million to $ 347.15 Million, with a yearly change of 1.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥347.15 Million | -29.18% |
| 2025 | CN¥490.15 Million | +31.55% |
| 2024 | CN¥372.59 Million | -7.55% |
| 2023 | CN¥403.02 Million | +16.65% |
| 2022 | CN¥345.49 Million | -26.63% |
| 2021 | CN¥470.87 Million | -18.33% |
| 2020 | CN¥576.52 Million | -23.75% |
| 2019 | CN¥756.04 Million | +147.83% |
| 2018 | CN¥305.06 Million | -56.54% |
| 2017 | CN¥701.98 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Zhejiang Shengda Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $347.15 Million USD |
| MoneyControl | $347.15 Million USD |
| MarketWatch | $347.15 Million USD |
| marketcap.company | $347.15 Million USD |
| Reuters | $347.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.